- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06169241
Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients
April 7, 2026 updated by: Eduardo Tibirica, MD, PhD, National Institute of Cardiology, Laranjeiras, Brazil
Effect of Nitrate Supplementation on Blood Pressure and Systemic Microvascular Function of Resistant Hypertensive Patients
Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity.
High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death.
Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients.
However, studies are needed to evaluate its benefits in patients with AH.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eduardo Tibirica, MD, PhD
- Phone Number: +55-21-99914-6075
- Email: etibi@uol.com.br
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21040-360
- Recruiting
- National Institute of Cardiology
-
Contact:
- Eduardo Tibirica
- Phone Number: 2125921265
- Email: eitib@uol.com.br
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.
Exclusion Criteria:
- neoplasms
- heart failure
- use of medications with nitrate in their formula
- patients undergoing renal denervation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
The placebo group will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
|
The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
|
|
Active Comparator: Beetroot extract
Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
|
Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of blood pressure evolution
Time Frame: 60 days
|
Evaluation using Ambulatory Blood Pressure Monitoring: systolic, diastolic and mean arterial pressures
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
December 5, 2023
First Submitted That Met QC Criteria
December 5, 2023
First Posted (Actual)
December 13, 2023
Study Record Updates
Last Update Posted (Actual)
April 13, 2026
Last Update Submitted That Met QC Criteria
April 7, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 70847523.9.0000.5272
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
-
University of Sao Paulo General HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)Brazil
Clinical Trials on Beetroot extract
-
University of PernambucoCompleted
-
University of PernambucoCompletedCardiovascular Diseases | PreventionBrazil
-
Oxford Brookes UniversityNot yet recruitingHypertension | Type 2 Diabetes Mellitus | Autonomic Nervous System DiseasesUnited Kingdom
-
NIHR Exeter Clinical Research FacilityTorbay and South Devon NHS Foundation TrustCompleted
-
University of CoimbraRecruitingDiabete Mellitus | Small Vessel Cerebrovascular DiseasePortugal
-
Bangor UniversityCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
Western Norway University of Applied SciencesCompleted
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted